Monthly Archives: August 2021

Second authorization to resume patient enrollment, in the Phase 3 study of masitinib in mastocytosis

25/08/2021 – AB Science announced today that it has received authorization from the French National Agency (ANSM) to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB15003) in mastocytosis

First authorization to resume patient enrollment in the Phase 3 study of masitinib in ALS

23/08/2021 – AB Science today announced that it has received the first authorization to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in amyotrophic lateral sclerosis (ALS)

Publication of a pathogenic mechanism triggered by mast cells in the ALS spinal cord that can be targeted by masitinib

19/08/2021 – AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the amyotrophic lateral sclerosis (ALS) spinal cord that can be targeted by masitinib

Q&A press release following-up on the June 28, 2021 press release relating to an agreement with historical shareholders

06/08/2021 – AB Science publishes a Q&A press release, following-up on its June 28, 2021 press release relating to an agreement with historical shareholders